

ASX Release 5 October 2018

ASX code: PIQ

LABORATORIES LTD

Proteomics International receives \$928k from sale of shareholding in CPR Pharma Services

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) advises it has completed the sale of its shareholding in CPR Pharma Services Pty Ltd (CPR) with the receipt of \$928,399.

The sale was announced last month and completed as expected [ASX: 10 September 2018].

The MOU between Proteomics International and CPR remains in place, targeting advanced diagnostics and analytical services for clinical trials [ASX: 2 February 2018].

ENDS

For further information please contact:

Dr Richard Lipscombe

Managing Director

Proteomics International Laboratories Ltd

T: +61 8 9389 1992

E: enquiries@proteomicsinternational.com

Digital Mantra Group T: +61 2 8218 2144 E: team@dmgpr.com

Susan Fitzpatrick-Napier

[Public Relations & Media Contact]

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on Perth's QEII Medical Campus.

Proteomics International's business model is centred on the commercialisation of the company's world-leading test for diabetic kidney disease, PromarkerD, whilst using its proprietary Promarker™ technology platform to create a pipeline of novel diagnostic tests, and offset the cash burn from R&D and product development through provision of specialist analytical services.